Inuvair

Beclometasone dipropionate and Formoterol fumarate, the active ingredients in Inuvair, are an inhaled corticosteroid/long‑acting β2‑agonist combination presented as a fixed‑dose inhalation spray for inhalation use. The product provides anti‑inflammatory and bronchodilator effects for the maintenance treatment of asthma and chronic obstructive pulmonary disease in adults and adolescents.

GNH USA supplies Inuvair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. The company provides reliable logistics and supports import documentation for global markets.

Inuvair, a fixed‑dose inhaled corticosteroid/long‑acting β2‑agonist combination, is used in the respiratory disease pathway for maintenance therapy.

Asthma: reduces airway inflammation and improves airflow for long‑term control. Chronic obstructive pulmonary disease (COPD): provides bronchodilation and anti‑inflammatory action to decrease exacerbations. Exercise‑induced bronchoconstriction: helps maintain open airways during physical activity. Bronchial hyperresponsiveness: stabilises airway tone and reduces symptom frequency.

Inuvair may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Throat irritation or soreness. - Hoarseness or voice changes. - Oral candidiasis (thrush). - Cough or wheezing after inhalation.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Adrenal suppression with prolonged high‑dose use. - Severe hypersensitivity reactions, including anaphylaxis. - Cardiac arrhythmias or tachycardia. - Pneumonia, especially in COPD patients.

Before prescribing Inuvair, clinicians should consider several safety measures.

Assess infection risk: evaluate for active respiratory infections prior to initiation. Monitor growth in children: perform periodic assessment of growth velocity. Use spacer device: reduce oropharyngeal deposition and improve drug delivery. Avoid abrupt discontinuation: taper under medical supervision to prevent loss of disease control. Store at ambient temperature: keep inhaler in original container, protect from moisture and heat.

Inuvair can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase systemic exposure to beclometasone.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalaemia risk when combined with a β2‑agonist. - Theophylline: additive bronchodilator effect; monitor serum levels. - Live attenuated vaccines: corticosteroid component may reduce vaccine efficacy.